Research & Development
Tikcro Technologies incurs lower net loss of USD341,000 for Q2 2018
18 September 2018 -

Cancer immune-therapy company Tikcro Technologies Ltd (OTCQB:TIKRF) stated on Monday that it recorded a net loss of USD341,000 (USD0.03 per diluted share) for the second quarter ended 30 June 2018.

This is a rise in earnings when compared with a higher net loss of USD407,000 (USD0.04 per diluted share) for the same period last year.

Research and development expenses of USD188,000 and USD214,000 were recorded for Q2 2018 and Q2 2017 respectively.

As of 30 June 2018, the company announced USD5.8m in cash, cash equivalents and short-term bank deposits.

The company added that the US Food and Drug Administration (FDA) recently approved a combination treatment of a CTLA-4 antibody with a PD-1 antibody for intermediate and poor-risk patients with advanced renal cell carcinoma (RCC) and sub-types of metastatic colorectal cancer (mCRC).



Related Headlines